A double-blind placebo-controlled trial of a leukotriene receptor antagonist in chronic pancreatitis in humans

Double Blind ◽

Double Blind Placebo ◽

Leukotriene Receptor

The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial

European Journal of Pharmacology ◽

10.1016/j.ejphar.2021.174295 ◽

2021 ◽

pp. 174295

Author(s):

Mahmoud Samy Abdallah ◽

Ahmed Hossam Eldeen ◽

Sally Said Tantawy ◽

Tarek Mohamed Mostafa

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽

Leukotriene Receptor

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid

Clinical & Experimental Allergy ◽

10.1046/j.1365-2222.2001.01189.x ◽

2001 ◽

Vol 31 (10) ◽

pp. 1607-1614 ◽

Cited By ~ 109

Author(s):

M. L. Pacor ◽

G. Di Lorenzo ◽

R. Corrocher

Keyword(s):

Acetylsalicylic Acid ◽

Receptor Antagonist ◽

Chronic Urticaria ◽

Food Additive ◽

Double Blind ◽

Double Blind Placebo ◽

Leukotriene Receptor

Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist

Journal of Asthma ◽

10.3109/02770909709067222 ◽

1997 ◽

Vol 34 (4) ◽

pp. 321-328 ◽

Cited By ~ 60

Author(s):

Jay Grossman ◽

Isidore Faiferman ◽

Jeffrey W. Dubb ◽

Debra J. Tompson ◽

William Busse ◽

...

Keyword(s):

Clinical Study ◽

Receptor Antagonist ◽

Double Blind ◽

Double Blind Placebo ◽

Leukotriene Receptor ◽

Multicenter Clinical Study

A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia

European Journal of Pain ◽

10.1016/j.ejpain.2010.09.013 ◽

2011 ◽

Vol 15 (5) ◽

pp. 509-514 ◽

Cited By ~ 24

Author(s):

Pascale Vergne-Sallel ◽

Carine Dufauret-Lombardl ◽

Christine Bonnetl ◽

Anne Simonl ◽

Richard Trèvesl ◽

...

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Double Blind ◽

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.134254 ◽

2010 ◽

Vol 70 (5) ◽

pp. 747-754 ◽

Cited By ~ 314

Author(s):

P. Quartier ◽

F. Allantaz ◽

R. Cimaz ◽

P. Pillet ◽

C. Messiaen ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Systemic Onset

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine ◽

10.1007/s12020-018-1597-1 ◽

2018 ◽

Vol 62 (2) ◽

pp. 371-380 ◽

Cited By ~ 4

Author(s):

Barry Gumbiner ◽

Brooke Esteves ◽

Vanessa Dell ◽

Tenshang Joh ◽

Pamela D. Garzone ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Phase 1 ◽

Double Blind ◽

Glucagon Receptor ◽

Double Blind Placebo ◽

Dose Study ◽

Glucagon Receptor Antagonist

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Author response for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/response1 ◽

2019 ◽

Author(s):

Marie Louise Johansen ◽

Morten Schou ◽

Patrick Rossignol ◽

Maria Refsgaard Holm ◽

Jon Rasmussen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Liver Fat ◽

Author Response ◽

Double Blind ◽

Decision letter for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v1/review3 ◽

2019 ◽

Author(s):

Ahmed Alshawi

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽